LIPO — LIPELLA PHARMACEUTICALS INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1347242 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -720,973 | -1,274,272 | -1,254,078 | 2,349,810 | 1,855,771 | 862,215 |
| Jun 2025 | 0 | -791,581 | -1,356,575 | -1,327,486 | 3,720,206 | 2,781,828 | 978,534 |
| Mar 2025 | 0 | -993,475 | -1,327,821 | -1,306,523 | 4,856,051 | 4,225,012 | 776,847 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,785,321
Investing CF
$0
Financing CF
$3,456,228
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.23
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-19,228,194
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-3,958,668
Pretax Income TTM
$-3,888,087
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$389,783
EBITDA
$-5,407,074
Free Cash Flow
$-2,827,184
Enterprise Value
$-1,589,376
Total Cash
$1,855,771
Total Debt
$264,083
Shares Out
4,620,837
Trailing EPS
$-2.26
Book Value
$0.32
ROE
-361.8%
ROA
-149.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 536,357 | -5,080,542 | -5,016,264 | 2,673,870 | 754,417 | 1,919,453 | -3,950,747 |
| Dec 2023 | 449,617 | -4,745,953 | -4,618,965 | 3,577,174 | 432,726 | 3,144,448 | -3,150,172 |
| Dec 2022 | 184,156 | -2,589,713 | -2,597,692 | 5,950,000 | 1,274,514 | 4,675,596 | -1,831,161 |
| Dec 2021 | 259,347 | -1,915,828 | -1,865,473 | 2,012,889 | 589,337 | 1,423,552 | -989,271 |
TTM Snapshot
Revenues TTM
$409,977
NetIncome TTM
$-5,329,759
OpCashFlow TTM
—
Assets (Latest)
$2,349,810
Forward EPS
$-3.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Lipella Pharmaceuticals files for bankruptcy protection four years after going public
2026-04-02 16:53 · Yahoo
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
2026-03-31 00:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.